Literature DB >> 18385327

Long-distance retrograde effects of botulinum neurotoxin A.

Flavia Antonucci1, Chiara Rossi, Laura Gianfranceschi, Ornella Rossetto, Matteo Caleo.   

Abstract

Botulinum neurotoxins (designated BoNT/A-BoNT/G) are bacterial enzymes that block neurotransmitter release by cleaving essential components of the vesicle fusion machinery. BoNT/A, which cleaves SNAP-25 (synaptosomal-associated protein of 25 kDa), is extensively exploited in clinical medicine to treat neuromuscular pathologies, facial wrinkles, and various types of pain. It is widely assumed that BoNT/A remains at the synaptic terminal and its effects are confined to the injection site. Here we demonstrate that catalytically active BoNT/A is retrogradely transported by central neurons and motoneurons and is then transcytosed to afferent synapses, in which it cleaves SNAP-25. SNAP-25 cleavage by BoNT/A was observed in the contralateral hemisphere after unilateral BoNT/A delivery to the hippocampus. Appearance of cleaved SNAP-25 resulted in blockade of hippocampal activity in the untreated hemisphere. Injections of BoNT/A into the optic tectum led to the appearance of BoNT/A-truncated SNAP-25 in synaptic terminals within the retina. Cleaved SNAP-25 also appeared in the facial nucleus after injection of the toxin into rat whisker muscles. Experiments excluded passive spread of the toxin and demonstrated axonal migration and neuronal transcytosis of BoNT/A. These findings reveal a novel pathway of BoNT/A trafficking in neurons and have important implications for the clinical uses of this neurotoxin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385327      PMCID: PMC6671090          DOI: 10.1523/JNEUROSCI.0375-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  125 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 3.  Evidence-based knee injections for the management of arthritis.

Authors:  Olivia T Cheng; Dmitri Souzdalnitski; Bruce Vrooman; Jianguo Cheng
Journal:  Pain Med       Date:  2012-05-23       Impact factor: 3.750

Review 4.  Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.

Authors:  Christopher Dowson; Mohammad Shamim Khan; Prokar Dasgupta; Arun Sahai
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

5.  Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism.

Authors:  Callista B Harper; Sally Martin; Tam H Nguyen; Shari J Daniels; Nickolas A Lavidis; Michel R Popoff; Gordana Hadzic; Anna Mariana; Ngoc Chau; Adam McCluskey; Phillip J Robinson; Frederic A Meunier
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

Review 6.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

7.  Healing beauty? More biotechnology cosmetic products that claim drug-like properties reach the market.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2008-11       Impact factor: 8.807

Review 8.  The role of botulinum neurotoxin in pain management--an ongoing controversy.

Authors:  Avi Ashkenazi
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 9.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.